These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26627251)

  • 1. Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.
    Gavrilov K; Seo YE; Tietjen GT; Cui J; Cheng CJ; Saltzman WM
    Proc Natl Acad Sci U S A; 2015 Dec; 112(48):E6597-605. PubMed ID: 26627251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
    Withey JM; Harvey AJ; Crompton MR
    Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
    Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
    Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562].
    Wang W; DU Y; Lin GQ; Li NN; Sun BZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):606-11. PubMed ID: 20561411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
    Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
    J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
    Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT
    Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
    Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions.
    Koldehoff M
    Methods Mol Biol; 2015; 1218():277-92. PubMed ID: 25319658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
    Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
    FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
    Ohba H; Zhelev Z; Bakalova R; Ewis A; Omori T; Ishikawa M; Shinohara Y; Baba Y
    Cancer; 2004 Sep; 101(6):1390-403. PubMed ID: 15368327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
    Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
    J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
    Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
    Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
    Bártová E; Harnicarová A; Pacherník J; Kozubek S
    Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
    Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
    J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
    Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
    Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient silencing of bcr/abl oncogene by single- and double-stranded siRNAs targeted against b2a2 transcripts.
    Rapozzi V; Xodo LE
    Biochemistry; 2004 Dec; 43(51):16134-41. PubMed ID: 15610007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates.
    Shinkai Y; Kashihara S; Minematsu G; Fujii H; Naemura M; Kotake Y; Morita Y; Ohnuki K; Fokina AA; Stetsenko DA; Filichev VV; Fujii M
    Nucleic Acid Ther; 2017 Jun; 27(3):168-175. PubMed ID: 28355131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
    Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
    Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
    Koldehoff M; Elmaagacli AH
    Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.